The complex interactions of p53 with target DNA: We learn as we go

Biochemistry and Cell Biology

Volumn 81, Issue 3, 2003, Pages 141-150

  Kim, Ella ^a   Deppert, Wolfgang ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Chromatin; Chromatin remodeling; DNA conformation; Sequence specific DNA binding; Tumor suppressor p53

Indexed keywords

BINDING ENERGY; CHEMICAL ACTIVATION; COMPLEXATION; GENETIC ENGINEERING; TUMORS;

TRANSACTIVATORS;

DNA;

DNA; PROTEIN P53;

AMINO ACID SEQUENCE; CHROMATIN; COMPLEX FORMATION; CONFERENCE PAPER; DNA STRUCTURE; GENE CONTROL; GENE TARGETING; MODEL; NONHUMAN; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; STRESS;

CHROMATIN; DNA; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0042763553     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/o03-046     Document Type: Conference Paper

References (97)

1. Ahn, J., and Prives, C. 2001. The C-terminus of p53: the more you learn the less you know. Nat. Struct. Biol. 8: 730-732.
2. Avantaggiati, M.L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A.S., and Kelly, K. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell, 89: 1175-1184.
3. Bakkenist, C.J., and Kastan, M.B. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature (London), 421: 499-506.
4. Balagurumoorthy, P., Lindsay, S.M., and Harrington, R.E. 2002. Atomic force microscopy reveals kinks in the p53 response element DNA. Biophys. Chem. 101-102: 611-623.
5. Barlev, N.A., Liu, L., Chehab, N.H., Mansfield, K., Harris, K.G., Halazonetis, T.D., and Berger, S.L. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell, 8: 1243-1254.
6. Bourdon, J.C., Deguin-Chambon, V., Lelong, J.C., Dessen, P., May, P., Debuire, B., and May, E. 1997. Further characterisation of the p53 responsive element - Identification of new candidate genes for trans-activation by p53. Oncogene, 14: 85-94.
7. Braastad, C.D., Han, Z., and Hendrickson, E.A. 2002. Constitutive DNaseI hypersensitivity of p53-regulated promoters. J. Biol. Chem. 9: 9.
8. Brazdova, M., Palecek, J., Cherny, D.I., Billova, S., Fojta, M., Pecinka, P., Vojtesek, B., Jovin, T.M., and Palecek, E. 2002. Role of tumor suppressor p53 domains in selective binding to supercoiled DNA. Nucleic Acids Res. 30: 4966-4974.
9. Bullock, A.N., and Fersht, A.R. 2001. Rescuing the function of mutant p53. Nat. Rev. Cancer, 1: 68-76.
10. Cain, C., Miller, S., Ahn, J., and Prives, C. 2000. The N terminus of p53 regulates its dissociation from DNA. J. Biol. Chem. 275: 39 944-39 953.
11. Chene, P. 2001. The role of tetramerization in p53 function. Oncogene, 20: 2611-2617.
12. Cho, Y., Gorina, S., Jeffrey, P.D., and Pavletich, N.P. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Washington, D.C.), 265: 346-355.
13. Contente, A., Dittmer, A., Koch, M.C., Roth, J., and Dobbelstein, M. 2002. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat. Genet. 30: 315-320.
14. Cowell, I.G., Okorokov, A.L., Cutts, S.A., Padget, K., Bell, M., Milner, J., and Austin, C.A. 2000. Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53. Exp. Cell Res. 255: 86-94.
15. Degtyareva, N., Subramanian, D., and Griffith, J.D. 2001. Analysis of the binding of p53 to DNAs containing mismatched and bulged bases. J. Biol. Chem. 276: 8778-8784.
16. Deppert, W. 1996. Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions. J. Cell Biochem. 62: 172-180.
17. Dornan, D., Shimizu, H., Perkins, N.D., and Hupp, T.R. 2002. DNA-dependent acetylation of p53 by the transcription coactivator p300. J. Biol. Chem. 23: 23.
18. el-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W., and Vogelstein, B. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1: 45-49.
19. Espinosa, J.M., and Emerson, B.M. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell, 8: 57-69.
20. Gobert, C., Skladanowski, A., and Larsen, A.K. 1999. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. Proc. Natl. Acad. Sci. U.S.A. 96: 10 355-10 360.
21. Gohler, T., Reimann, M., Cherny, D., Walter, K., Warnecke, G., Kim, E., and Deppert, W. 2002. Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain. J. Biol. Chem. 277: 41 192-41 203.
22. Gottifredi, V., Shieh, S., Taya, Y., and Prives, C. 2001. From the Cover: p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc. Natl. Acad. Sci. U.S.A. 98: 1036-1041.
23. Graunke, D.M., Fornace, A.J., Jr., and Pieper, R.O. 1999. Presetting of chromatin structure and transcription factor binding poise the human GADD45 gene for rapid transcriptional up-regulation. Nucleic Acids Res. 27: 3881-3890.
24. Gu, W., and Roeder, R.G. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 90: 595-606.
25. Gu, W., Shi, X.L., and Roeder, R.G. 1997. Synergistic activation of transcription by CBP and p53. Nature (London), 387: 819-823.
26. Halazonetis, T.D., and Kandil, A.N. 1993. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12: 5057-5064.
27. Hoh, J., Jin, S., Parrado, T., Edington, J., Levine, A.J., and Ott, J. 2002. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. U.S.A. 99: 8467-8472.
28. Horn, P.J., and Peterson, C.L. 2002. Molecular biology. Chromatin higher order folding - wrapping up transcription. Science (Washington, D.C.), 297: 1824-1827.
29. Hupp, T.R., and Lane, D.P. 1994a. Allosteric activation of latent p53 tetramers. Curr. Biol. 4: 865-875.
30. Hupp, T.R., and Lane, D.P. 1994b. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harb. Symp. Quant. Biol. 59: 195-206.
31. Hupp, T.R., and Lane, D.P. 1995. Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J. Biol. Chem. 270: 18 165-18 174.
32. Hupp, T.R., Meek, D.W., Midgley, C.A., and Lane, D.P. 1992. Regulation of the specific DNA binding function of p53. Cell, 71: 875-886.
33. Igata, E., Inoue, T., Ohtani-Fujita, N., Sowa, Y., Tsujimoto, Y., and Sakai, T. 1999. Molecular cloning and functional analysis of the murine bax gene promoter. Gene, 238: 407-415.
34. Inga, A., Storici, F., Darden, T.A., and Resnick, M.A. 2002. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol. Cell. Biol. 22: 8612-8625.
35. Jayaraman, L., Moorthy, N.C., Murthy, K.G., Manley, J.L., Bustin, M., and Prives, C. 1998. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 12: 462-472.
36. Jeffrey, P.D., Gorina, S., and Pavletich, N.P. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (Washington, D.C.), 267: 1498-1502.
37. Jett, S.D., Cherny, D.I., Subramaniam, V., and Jovin, T.M. 2000. Scanning force microscopy of the complexes of p53 core domain with supercoiled DNA. J. Mol. Biol. 299: 585-592.
38. Kaeser, M.D., and Iggo, R.D. 2002. From the Cover: Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity invivo. Proc. Natl. Acad. Sci. U.S.A. 99: 95-100.
39. Kern, S.E., Kinzler, K.W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., and Vogelstein, B. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science (Washington, D.C.), 252: 1708-1711.
40. Khanna, K.K., and Jackson, S.P. 2001. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27: 247-254.
41. Kim, E., Albrechtsen, N., and Deppert, W. 1997. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. Oncogene, 15: 857-869.
42. Kim, E., Rohaly, G., Heinrichs, S., Gimnopoulos, D., Meissner, H., and Deppert, W. 1999. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53. Oncogene, 18: 7310-7318.
43. Kingston, R.E., and Narlikar, G.J. 1999. ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev. 13: 2339-2352.
44. Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y., Lowe, S.W., Kastan, M., and Giaccia, A. 2001. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell Biol. 21: 1297-1310.
45. Lane, D.P. 1992. Cancer. p53, guardian of the genome. Nature (London), 358: 15-16.
46. Lane, D.P., and Crawford, L.V. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature (London), 278: 261-263.
47. Lane, D.P., and Gannon, J. 1983. Cellular proteins involved in SV40 transformation. Cell Biol. Int. Rep. 7: 513-514.
48. Lee, S., Elenbaas, B., Levine, A., and Griffith, J. 1995. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell, 81: 1013-1020.
49. Lee, S., Cavallo, L., and Griffith, J. 1997. Human p53 binds Holliday junctions strongly and facilitates their cleavage. J. Biol. Chem. 272: 7532-7539.
50. Lee, D., Kim, J.W., Seo, T., Hwang, S.G., Choi, E.J., and Choe, J. 2002. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J. Biol. Chem. 277: 22 330-22 337.
51. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331.
52. Lill, N.L., Grossman, S.R., Ginsberg, D., DeCaprio, J., and Livingston, D.M. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature (London), 387: 823-827.
53. Linzer, D.I., and Levine, A.J. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell, 17: 43-52.
54. Liu, L., Scolnick, D.M., Trievel, R.C., Zhang, H.B., Marmorstein, R., Halazonetis, T.D., and Berger, S.L. 1999. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell Biol. 19: 1202-1209.
55. Mao, Y., Mehl, I.R., and Muller, M.T. 2002. Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status. Proc. Natl. Acad. Sci. U.S.A. 99: 1235-1240.
56. Martinez, J.D., Craven, M.T., and Pennington, M.E. 1998. Selective binding of different p53 response elements by p53 containing complexes. Oncogene, 16: 453-458.
57. McCoy, M., Stavridi, E.S., Waterman, J.L., Wieczorek, A.M., Opella, S.J., and Halazonetis, T.D. 1997. Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J. 16: 6230-6236.
58. McKinney, K., and Prives, C. 2002. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell Biol. 22: 6797-6808.
59. Milner, J. 1984. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature (London), 310: 143-145.
60. Milner, J. 1995. Flexibility: the key to p53 function? Trends Biochem. Sci. 20: 49-51.
61. Milyavsky, M., Mimran, A., Senderovich, S., Zurer, I., Erez, N., Shats, I., Goldfinger, N., Cohen, I., and Rotter, V. 2001. Activation of p53 protein by telomeric (TTAGGG)n repeats. Nucleic Acids Res. 29: 5207-5215.
62. Miyashita, T., and Reed, J.C. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80: 293-299.
63. Muller, B.F., Paulsen, D., and Deppert, W. 1996. Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene, 12: 1941-1952.
64. Muller-Tiemann, B.F., Halazonetis, T.D., and Elting, J.J. 1998. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl. Acad. Sci. U.S.A. 95: 6079-6084.
65. Murphy, M., Ahn, J., Walker, K.K., Hoffman, W.H., Evans, R.M., Levine, A.J., and George, D.L. 1999. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13: 2490-2501.
66. Nagaich, A.K., Appella, E., and Harrington, R.E. 1997. DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53. J. Biol. Chem. 272: 14 842-14 849.
67. Nakamura, S., Roth, J.A., and Mukhopadhyay, T. 2000. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol. Cell Biol. 20: 9391-9398.
68. Ogden, S.K., Lee, K.C., Wernke-Dollries, K., Stratton, S.A., Aronow, B., and Barton, M.C. 2001. p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression. J. Biol. Chem. 276: 42 057-42 062.
69. Palecek, E., Vlk, D., Stankova, V., Brazda, V., Vojtesek, B., Hupp, T.R., Schaper, A., and Jovin, T.M. 1997. Tumor suppressor protein p53 binds preferentially to supercoiled DNA. Oncogene, 15: 2201-2209.
70. Palecek, E., Brazdova, M., Brazda, V., Palecek, J., Billova, S., Subramaniam, V., and Jovin, T.M. 2001. Binding of p53 and its core domain to supercoiled DNA. Eur. J. Biochem. 268: 573-581.
71. Pearson, C.E., Zorbas, H., Price, G.B., and Zannis-Hadjopoulos, M. 1996. Inverted repeats, stem-loops, and cruciforms: significance for initiation of DNA replication. J. Cell Biochem. 63: 1-22.
72. Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W., and Vogelstein, B. 1997. A model for p53-induced apoptosis. Nature (London), 389: 300-305.
73. Qian, H., Wang, T., Naumovski, L., Lopez, C.D., and Brachmann, R.K. 2002. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene, 21: 7901-7911.
74. Raj, K., Ogston, P., and Beard, P. 2001. Virus-mediated killing of cells that lack p53 activity. Nature (London), 412: 914-917.
75. Resnick-Silverman, L., St. Clair, S., Maurer, M., Zhao, K., and Manfredi, J.J. 1998. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev. 12: 2102-2107.
76. Saintigny, Y., Rouillard, D., Chaput, B., Soussi, T., and Lopez, B.S. 1999. Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint. Oncogene, 18: 3553-3563.
77. Schmidt, T., Korner, K., Karsunky, H., Korsmeyer, S., Muller, R., and Moroy, T. 1999. The activity of the murine Bax promoter is regulated by Sp1/3 and E-box binding proteins but not by p53. Cell Death Differ. 6: 873-882.
78. Scolnick, D.M., Chehab, N.H., Stavridi, E.S., Lien, M.C., Caruso, L., Moran, E., Berger, S.L., and Halazonetis, T.D. 1997. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 57: 3693-3696.
79. Soussi, T., and Beroud, C. 2001. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer, 1: 233-240.
80. Stansel, R.M., Subramanian, D., and Griftith, J.D. 2002. p53 binds telomeric single strand overhangs and t-loop junctions in vitro. J. Biol. Chem. 277: 11 625-11 628.
81. Steinmeyer, K., and Deppert, W. 1988. DNA binding properties of murine p53. Oncogene, 3: 501-507.
82. Szak, S.T., Mays, D., and Pietenpol, J.A. 2001. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell Biol. 21: 3375-3386.
83. Thornborrow, E.C., and Manfredi, J.J. 1999. One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. J. Biol. Chem. 274: 33 747-33 756.
84. Thornborrow, E.C., Patel, S., Mastropietro, A.E., Schwartzfarb, E.M., and Manfredi, J.J. 2002. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene, 21: 990-999.
85. Tokino, T., Thiagalingam, S., el-Deiry, W.S., Waldman, T., Kinzler, K.W., and Vogelstein, B. 1994. p53 tagged sites from human genomic DNA. Hum. Mol. Genet. 3: 1537-1542.
86. van Holde, K., and Zlatanova, J. 1994. Unusual DNA structures, chromatin and transcription. Bioessays, 16: 59-68.
87. Vogelstein, B., Lane, D., and Levine, A.J. 2000. Surfing the p53 network. Nature (London), 408: 307-310.
88. Wang, Y., and Prives, C. 1995. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature (London), 376: 88-91.
89. Wang, Y., Schwedes, J.F., Parks, D., Mann, K., and Tegtmeyer, P. 1995. Interaction of p53 with its consensus DNA-binding site. Mol. Cell Biol. 15: 2157-2165.
90. Wang, T., Kobayashi, T., Takimoto, R., Denes, A.E., Snyder, E.L., el-Deiry, W.S., and Brachmann, R.K. 2001. hADA3 is required for p53 activity. EMBO J. 20: 6404-6413.
91. Ward, G.K., McKenzie, R., Zannis-Hadjopoulos, M., and Price, G.B. 1990. The dynamic distribution and quantification of DNA cruciforms in eukaryotic nuclei. Exp. Cell Res. 188: 235-246.
92. Waterman, J.L., Shenk, J.L., and Halazonetis, T.D. 1995. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14: 512-519.
93. Will, K., Warnecke, G., Albrechtsen, N., Boulikas, T., and Deppert, W. 1998. High affinity MAR-DNA binding is a common property of murine and human mutant p53. J. Cell. Biochem. 69: 260-270.
94. Xiao, G., White, D., and Bargonetti, J. 1998. p53 binds to a constitutively nucleosome free region of the mdm2 gene. Oncogene, 16: 1171-1181.
95. Yang, Q., Zhang, R., Wang, X.W., Spillare, E.A., Linke, S.P., Subramanian, D., Griffith, J.D., Li, J.L., Hickson, I.D., Shen, J.C., Loeb, L.A., Mazur, S.J., Appella, E., Brosh, R.M., Jr., Karmakar, P., Bohr, V.A., and Harris, C.C. 2002. The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J. Biol. Chem. 277: 31 980-31 987.
96. Zhang, W., Guo, X.Y., and Deisseroth, A.B. 1994. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element. Oncogene, 9: 2513-2521.
97. Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W.H., Tom, E., Mack, D.H., and Levine, A.J. 2000. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14: 981-993.